Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuroscience, and oncology. Our team works collaboratively and relentlessly to advance our therapies; all with the goal of improving the lives of patients, their families, and their caregivers.

The Radius portfolio consists of commercial and clinical development assets, that include early to late-stage drug candidates.

In the area of bone health, we are dedicated to serving those patients suffering from bone loss such as the 8.9 million osteoporotic fractures that occur annually worldwide according to the International Osteoporosis Foundation. In 2017, we launched our first commercial product in the U.S. for post-menopausal women with osteoporosis at high risk for fracture. In October 2021, Radius announced positive topline results from one of its late stage clinical trials and has another late stage clinical trial in progress.

Our neuroscience group is centered around the clinical development of our investigational synthetic cannabidiol oral solution (RAD011), which has potential utilization in multiple rare disease areas. We are initially focused on the treatment of Prader-Willi syndrome, which is a complex genetic disorder with clinical manifestations in the endocrine and neurological systems. The disease primarily impacts the pediatric patient community and continues into adulthood. Our team is driven by the needs of those suffering from neurological diseases and seeks to expand its initiatives to other neuroscience areas.

Radius entered into an exclusive global license agreement in July 2020 with Menarini Group for the development and commercialization of elacestrant, an investigative oral selective estrogen receptor degrader (SERD). In October 2021, the companies jointly announced positive topline results from the Phase 3 trial (EMERALD) evaluating elacestrant  as a hormonal treatment for postmenopausal breast cancer.

At Radius, we are motivated by making a difference: for our employees, our partners, and – most importantly – the lives of patients, their families, and their caregivers.